Expand CRNX Menu
CRNX MENU

CRNX Latest Press Releases

-- February 26, 2026 --

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- February 5, 2026 --

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March Globe Newswire 4:05 PM

-- January 26, 2026 --

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 Globe Newswire 5:00 PM

-- January 22, 2026 --

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) Globe Newswire 4:05 PM

-- January 12, 2026 --

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- January 6, 2026 --

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock Globe Newswire 9:22 PM

-- January 5, 2026 --

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock Globe Newswire 4:02 PM
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia Globe Newswire 8:00 AM

-- January 4, 2026 --

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia Globe Newswire 4:00 PM

-- December 18, 2025 --

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 4:05 PM

-- December 11, 2025 --

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Globe Newswire 4:05 PM

-- December 10, 2025 --

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:34 PM

-- December 3, 2025 --

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors Globe Newswire 8:00 AM

-- November 20, 2025 --

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome Globe Newswire 4:05 PM

-- November 10, 2025 --

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:28 PM

-- November 6, 2025 --

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- October 23, 2025 --

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes